RU2754761C2 - Композиции, содержащие уролитины - Google Patents

Композиции, содержащие уролитины Download PDF

Info

Publication number
RU2754761C2
RU2754761C2 RU2018108136A RU2018108136A RU2754761C2 RU 2754761 C2 RU2754761 C2 RU 2754761C2 RU 2018108136 A RU2018108136 A RU 2018108136A RU 2018108136 A RU2018108136 A RU 2018108136A RU 2754761 C2 RU2754761 C2 RU 2754761C2
Authority
RU
Russia
Prior art keywords
urolithin
composition
particle size
medium chain
muscle
Prior art date
Application number
RU2018108136A
Other languages
English (en)
Russian (ru)
Other versions
RU2018108136A (ru
RU2018108136A3 (cg-RX-API-DMAC10.html
Inventor
Пенелопа АНДРЁ
Кристофер РИНШ
Уильям БЛАНКО-БОЗЕ
Original Assignee
Амазентис Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амазентис Са filed Critical Амазентис Са
Publication of RU2018108136A publication Critical patent/RU2018108136A/ru
Publication of RU2018108136A3 publication Critical patent/RU2018108136A3/ru
Application granted granted Critical
Publication of RU2754761C2 publication Critical patent/RU2754761C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018108136A 2015-08-28 2016-08-26 Композиции, содержащие уролитины RU2754761C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions
GB1515387.7 2015-08-28
PCT/EP2016/070255 WO2017036992A1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds

Publications (3)

Publication Number Publication Date
RU2018108136A RU2018108136A (ru) 2019-09-30
RU2018108136A3 RU2018108136A3 (cg-RX-API-DMAC10.html) 2020-01-31
RU2754761C2 true RU2754761C2 (ru) 2021-09-07

Family

ID=54326542

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018108136A RU2754761C2 (ru) 2015-08-28 2016-08-26 Композиции, содержащие уролитины

Country Status (15)

Country Link
US (5) US10695320B2 (cg-RX-API-DMAC10.html)
EP (1) EP3340977B1 (cg-RX-API-DMAC10.html)
JP (3) JP7227003B2 (cg-RX-API-DMAC10.html)
KR (2) KR102660005B1 (cg-RX-API-DMAC10.html)
CN (1) CN108289879B (cg-RX-API-DMAC10.html)
AU (1) AU2016314987B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018003745B1 (cg-RX-API-DMAC10.html)
CA (1) CA2996724C (cg-RX-API-DMAC10.html)
ES (1) ES2936723T3 (cg-RX-API-DMAC10.html)
GB (1) GB201515387D0 (cg-RX-API-DMAC10.html)
MX (1) MX2018002543A (cg-RX-API-DMAC10.html)
PT (1) PT3340977T (cg-RX-API-DMAC10.html)
RU (1) RU2754761C2 (cg-RX-API-DMAC10.html)
SG (1) SG10202001793PA (cg-RX-API-DMAC10.html)
WO (1) WO2017036992A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2867867C1 (ru) * 2025-12-11 2026-08-11 Василий Игоревич Пустовойт Композиция специализированного пищевого продукта в капсулах для поддержки митохондриальной функции

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
EP4553071A3 (en) * 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
US20210267932A1 (en) 2018-05-15 2021-09-02 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods of using, and methods for preparing compounds
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
AU2021346837A1 (en) 2020-09-25 2023-03-02 Société des Produits Nestlé S. A. Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
JP7541673B2 (ja) * 2020-11-30 2024-08-29 国立研究開発法人産業技術総合研究所 筋ジストロフィーの抗炎症剤、筋ジストロフィーにおける抗炎症のための中心静脈栄養用組成物および筋ジストロフィーの抗炎症用食品組成物
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
JPWO2023199908A1 (cg-RX-API-DMAC10.html) * 2022-04-11 2023-10-19
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
WO2024142098A1 (en) * 2022-12-27 2024-07-04 Indian Institute Of Science A method for the treatment of epilepsy
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
EP4555997A1 (en) * 2023-11-15 2025-05-21 Science4Beauty Sp. z o.o. Water-soluble composition comprising urolithin
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
KR20250158913A (ko) 2024-04-30 2025-11-07 주식회사 파이안바이오테크놀로지 유로리틴을 함유하는 탈모완화제와 모발성장촉진제
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations
GB202416802D0 (en) 2024-11-14 2025-01-01 Amazentis Sa Urolithin combination

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282781A1 (en) * 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US20080031862A1 (en) * 2006-08-04 2008-02-07 Shibnath Ghosal Mitochondria-targeted antioxidants
RU2013134197A (ru) * 2010-12-23 2015-01-27 Амазентис Са Композиции и способы для улучшения функции митохондрий и лечения нейродегенеративных заболеваний и когнитивных расстройств
WO2015097231A1 (en) * 2013-12-24 2015-07-02 Amazentis Sa Prodrugs of urolitihns and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
JP2000507268A (ja) 1996-03-26 2000-06-13 イーライ・リリー・アンド・カンパニー ベンゾチオフェン類、それを含む製剤、および方法
WO1999053941A1 (fr) * 1998-04-15 1999-10-28 Shionogi & Co., Ltd. Preparations orales contenant des derives de trh
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
JP5147239B2 (ja) 2004-09-29 2013-02-20 三栄源エフ・エフ・アイ株式会社 コエンザイムｑ１０含有乳化組成物
EP2145904A1 (de) 2008-07-18 2010-01-20 Basf Se Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
CN104016951B (zh) 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
PL2550092T3 (pl) 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
JP2013544829A (ja) 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法
JP2012111712A (ja) 2010-11-25 2012-06-14 Toyo Capsule Kk 油性ビタミンｃ経口投与用組成物
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
US20140079729A1 (en) * 2012-09-14 2014-03-20 Natreon, Inc. Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282781A1 (en) * 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US20080031862A1 (en) * 2006-08-04 2008-02-07 Shibnath Ghosal Mitochondria-targeted antioxidants
RU2013134197A (ru) * 2010-12-23 2015-01-27 Амазентис Са Композиции и способы для улучшения функции митохондрий и лечения нейродегенеративных заболеваний и когнитивных расстройств
WO2015097231A1 (en) * 2013-12-24 2015-07-02 Amazentis Sa Prodrugs of urolitihns and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Navindra P. Seeram et al. "Pharmacokinetics and tissue disposition of urolithin A, an ellagitannin-derived metabolite, in mice", The FASEB Journal, 2007, Vol. 21, No. 6, P. A1081. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2867867C1 (ru) * 2025-12-11 2026-08-11 Василий Игоревич Пустовойт Композиция специализированного пищевого продукта в капсулах для поддержки митохондриальной функции
RU2867870C1 (ru) * 2025-12-11 2026-08-11 Василий Игоревич Пустовойт Композиция специализированного пищевого продукта в форме жидкого концентрата (шота) для поддержки митохондриальной функции и энергетического обмена

Also Published As

Publication number Publication date
JP7227003B2 (ja) 2023-02-21
US11925616B2 (en) 2024-03-12
RU2018108136A (ru) 2019-09-30
US11337957B2 (en) 2022-05-24
US20180243261A1 (en) 2018-08-30
KR20180037052A (ko) 2018-04-10
JP2018533618A (ja) 2018-11-15
US10695320B2 (en) 2020-06-30
BR112018003745B1 (pt) 2023-11-07
MX2018002543A (es) 2018-06-15
AU2016314987B2 (en) 2021-07-08
RU2018108136A3 (cg-RX-API-DMAC10.html) 2020-01-31
US20220323407A1 (en) 2022-10-13
CN108289879B (zh) 2026-05-26
US20200323818A1 (en) 2020-10-15
JP2025004129A (ja) 2025-01-14
AU2016314987A1 (en) 2018-03-29
KR102660005B1 (ko) 2024-04-22
CN108289879A (zh) 2018-07-17
CA2996724C (en) 2024-05-21
SG10202001793PA (en) 2020-04-29
EP3340977B1 (en) 2022-11-02
ES2936723T3 (es) 2023-03-21
CA2996724A1 (en) 2017-03-09
HK1257500A1 (en) 2019-10-25
WO2017036992A1 (en) 2017-03-09
BR112018003745A2 (pt) 2018-09-25
US20240148690A1 (en) 2024-05-09
US20260216125A1 (en) 2026-07-30
PT3340977T (pt) 2023-01-31
KR102822365B1 (ko) 2025-06-17
KR20240060826A (ko) 2024-05-08
JP2022177130A (ja) 2022-11-30
GB201515387D0 (en) 2015-10-14
EP3340977A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
US11925616B2 (en) Compositions comprising urolithin compounds
JP2023100869A (ja) 対象におけるマイトファジーを改善するための方法
JP7161402B2 (ja) ウロリチン化合物を含む組成物
JP2023100870A (ja) 対象におけるマイトファジーを改善するための方法
JP2019182881A (ja) 末梢神経障害の予防又は改善用組成物
CN111296584A (zh) 一种促进儿童身高增长和大脑发育的配方牦牛奶粉及制备方法
JP6675413B2 (ja) トコトリエノールを効果的に送達するための製剤
KR20250133322A (ko) 우롤리틴과 케톤체의 조합물
BR112019012741A2 (pt) composição, formulação, método para prevenir e/ou tratar caquexia em um indivíduo, uso da composição, e, produto de uso médico especial, produto de alimentos para uso específico de saúde, produto para alimentos para fins médicos especiais, produto de alimento para uso dietético especial, produto de nutrição médica e produto de alimento médico.
HK1257500B (en) Compositions comprising urolithin compounds
TW201233342A (en) Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child